SCHEMBL4122859

SCHEMBL4122859

CCc1ccc(NC(=O)Nc2cccc([N+](=O)[O-])c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.73
KMT2A Q03164 8/20 0.73
MAPT P10636 6/20 0.73
HTT P42858 5/20 0.73
DDX3X O00571 2/20 0.73
POLB P06746 2/20 0.73
CTDSP1 Q9GZU7 1/20 0.73
BAZ1A Q9NRL2 2/20 0.68
GAA P10253 3/20 0.67
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA5A P35218 1/20 0.64
CA9 Q16790 1/20 0.64
CA5B Q9Y2D0 1/20 0.64
ABCG2 Q9UNQ0 1/20 0.64
TP53 P04637 1/20 0.64
CASP3 P42574 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
SENP7 Q9BQF6 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118564 0.86 GAA (0.73) MEN1KMT2AMAPTHTTDDX3X
SCHEMBL11047722 0.86 MEN1 (0.74) MEN1KMT2AMAPTHTTPOLB
SCHEMBL4124277 0.86 MEN1 (0.74) MEN1KMT2AMAPTHTTPOLB
SCHEMBL1047211 0.85 MEN1 (1.00) MEN1KMT2AMAPTHTTDDX3X
SCHEMBL22092552 0.85 MEN1 (0.79) MEN1KMT2AMAPTHTTDDX3X
SCHEMBL6129390 0.84 MEN1 (0.90) MEN1KMT2AMAPTHTTDDX3X
SCHEMBL17084065 0.84 MEN1 (0.96) MEN1KMT2AMAPTHTTDDX3X
SCHEMBL4106750 0.83 MEN1 (0.68) MEN1KMT2AMAPTHTTDDX3X
SCHEMBL15132988 0.82 MEN1 (0.75) MEN1KMT2AMAPTHTTDDX3X
SCHEMBL22092547 0.82 MEN1 (0.79) MEN1KMT2AMAPTHTTDDX3X

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MEN1 3273/4885KMT2A 2807/4885MAPT 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.